(NASDAQ:NVAX) shareholders might be concerned after seeing the share price drop 15% in the last quarter. But that scarcely detracts from the really solid long term returns generated by the company ...

Investors in Novavax, Inc. (Symbol: NVAX) saw new options begin trading today, for the February 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NVAX ...

Shares of Novavax Inc. NVAX shed 3.02% to $9.32 Friday, on what proved to be an all-around rough trading session for the ...

Novavax (NVAX) and other vaccine developers rise as Investors react to rising flu and COVID-19 cases in the U.S. Read more ...

Below is Validea's guru fundamental report for NOVAVAX INC (NVAX). Of the 22 guru strategies we follow, NVAX rates highest using our Small-Cap Growth Investor model based on the published strategy ...

But the company trimmed its outlook. Is NVAX stock a sell in December 2024? Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Moderna leads vaccine rally amid rising respiratory infections, spurring investment in COVID-19, flu, and RSV solutions.

It has been about a month since the last earnings report for Novavax (NVAX). Shares have added about 13.6% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...

Novavax, Inc. (NASDAQ:NVAX – Get Free Report)’s share price traded down 5.8% during mid-day trading on Monday .The stock traded as low as $7.62 and last traded at $7.80. 1,894,875 shares ...

NVAX closed Thursday's trading at $9.02 ... views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...

Novavax (NVAX) announced progress in Q4 advancing its corporate growth strategy through its partnership with Sanofi (SNY). The company has achieved a milestone associated with its Phase 2/3 ...